Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$18.44 - $26.41 $1,106 - $1,584
60 Added 0.3%
19,829 $402,000
Q4 2023

Feb 13, 2024

SELL
$12.64 - $30.11 $998 - $2,378
-79 Reduced 0.4%
19,769 $445,000
Q3 2023

Nov 13, 2023

BUY
$16.64 - $25.32 $11,731 - $17,850
705 Added 3.68%
19,848 $330,000
Q2 2023

Aug 04, 2023

BUY
$21.59 - $27.88 $15,868 - $20,491
735 Added 3.99%
19,143 $469,000
Q1 2023

May 12, 2023

BUY
$23.46 - $36.44 $8,586 - $13,337
366 Added 2.03%
18,408 $444,000
Q4 2022

Feb 10, 2023

SELL
$27.82 - $44.16 $1,836 - $2,914
-66 Reduced 0.36%
18,042 $532,000
Q3 2022

Nov 14, 2022

BUY
$16.33 - $51.06 $4,180 - $13,071
256 Added 1.43%
18,108 $757,000
Q2 2022

Aug 12, 2022

SELL
$17.22 - $38.47 $19,699 - $44,009
-1,144 Reduced 6.02%
17,852 $502,000
Q1 2022

May 13, 2022

SELL
$32.6 - $53.05 $43,586 - $70,927
-1,337 Reduced 6.58%
18,996 $706,000
Q4 2021

Feb 11, 2022

SELL
$36.77 - $90.91 $22,356 - $55,273
-608 Reduced 2.9%
20,333 $889,000
Q3 2021

Nov 12, 2021

SELL
$41.79 - $135.3 $20,811 - $67,379
-498 Reduced 2.32%
20,941 $1.3 Million
Q2 2021

Aug 13, 2021

BUY
$32.15 - $89.72 $76,677 - $213,982
2,385 Added 12.52%
21,439 $1.83 Million
Q1 2021

May 07, 2021

BUY
$7.09 - $87.95 $354 - $4,397
50 Added 0.26%
19,054 $856,000
Q4 2020

Feb 12, 2021

BUY
$6.79 - $12.25 $34,941 - $63,038
5,146 Added 37.13%
19,004 $130,000
Q3 2020

Nov 04, 2020

SELL
$2.86 - $11.51 $900 - $3,625
-315 Reduced 2.22%
13,858 $160,000
Q2 2020

Aug 12, 2020

BUY
$2.04 - $9.64 $28,912 - $136,627
14,173 New
14,173 $44,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $94.2M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.